Reliability of the 4 Metre Gait Speed in Idiopathic Pulmonary Fibrosis

Reliability of the 4 Metre Gait Speed in Patients With Idiopathic Pulmonary Fibrosis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02445157

Acronym

IPFREL

Enrollment

Registered

2015-05-15

Start date

2015-02-28

Completion date

2015-08-31

Last updated

2015-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Pulmonary Fibrosis

Keywords

Gait speed, Functional outcome measure

Brief summary

This study is investigating the reliability of the 4 metre gait speed test (4MGS) in patients with a lung disease called Idiopathic Pulmonary Fibrosis (IPF).

Detailed description

This observational study is investigating a simple test of walking speed, measured using the 4 metre gait speed test (4MGS), in patients with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). Drug development for this disease is slow in part because there is a lack of reliable measurements that can assess effectiveness of treatment. Slow walking speed has been shown to relate to poor outcomes in older adults and people with another lung disease called Chronic Obstructive Pulmonary Disease (COPD. The investigators are interested to see whether usual walking speed is a reliable measure in patients with IPF as this will help inform us of its potential use as an outcome measure. To do this, participants who consent to taking part in the study will be timed walking at their usual walking speed over a distance of 4 metres (13.12 feet). Participants will be asked to do this twice with a rest in between if required. One week later, participants will be asked to repeat the walking tests again.

Interventions

OTHER4MGS

Measurement of usual gait speed over 4 metres (metres/second)

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* IPF diagnosis according to NICE guidelines * Provision of informed consent

Exclusion criteria

* Significant co-morbidities that would limit walking ability, exercise capacity or make exercise unsafe (e.g. unstable ischaemic heart disease, neuromuscular disease, severe hip/lower limb joint pain, peripheral vascular disease, lower limb amputation) * Any patient whom the chief investigator feels it is unsafe to exercise (e.g. unstable cardiovascular disease) * Any condition that precludes providing informed consent e.g. cognitive impairment or poor English

Design outcomes

Primary

Measure	Time frame	Description
4 metre gait speed	Change in gait speed measured at two timepoints one week apart	Measure of usual walking speed

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026